 Measurement of metabotropic glutamate receptor type 5 mGluR5 binding capacity in the brain, may be a valuable tool in the early detection, understanding, or evaluation of Parkinson disease PD, Huntington disease HD, Fragile X syndrome FXS, Autism Spectrum DisorderASD, Alzheimers DiseaseAD, and subjects with mild cognitive impairment MCI. 